Korean Drug Co. Ltd (014570) - Total Assets
Based on the latest financial reports, Korean Drug Co. Ltd (014570) holds total assets worth ₩96.39 Billion KRW (≈ $65.32 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can Korean Drug Co. Ltd service its debt to assess how comfortably operating cash covers total debt obligations.
Korean Drug Co. Ltd - Total Assets Trend (2014–2025)
This chart illustrates how Korean Drug Co. Ltd's total assets have evolved over time, based on quarterly financial data. See Korean Drug Co. Ltd (014570) net assets for net asset value and shareholders' equity analysis.
Korean Drug Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Korean Drug Co. Ltd's total assets of ₩96.39 Billion consist of 73.2% current assets and 26.8% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 5.2% |
| Accounts Receivable | ₩23.14 Billion | 24.5% |
| Inventory | ₩15.53 Billion | 16.5% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩208.77 Million | 0.2% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Korean Drug Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 014570 company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Korean Drug Co. Ltd's current assets represent 73.2% of total assets in 2025, an increase from 70.7% in 2014.
- Cash Position: Cash and equivalents constituted 5.2% of total assets in 2025, down from 5.3% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 24.5% of total assets.
Korean Drug Co. Ltd Competitors by Total Assets
Key competitors of Korean Drug Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biogen Inc
NASDAQ:BIIB
|
USA | $29.44 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$207.62 Billion |
|
AstraZeneca PLC
NYSE:AZN
|
USA | $114.02 Billion |
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436
|
China | CN¥18.38 Billion |
|
Aurora Optoelectronics Co Ltd
SHG:600666
|
China | CN¥2.22 Billion |
|
NanJing Pharmaceutical Co Ltd
SHG:600713
|
China | CN¥34.05 Billion |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
|
Brazil | R$3.66 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$2.28 Million |
Korean Drug Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.63 | 6.43 | 6.94 |
| Quick Ratio | 5.11 | 4.43 | 5.70 |
| Cash Ratio | 0.00 | 0.00 | 0.80 |
| Working Capital | ₩61.18 Billion | ₩55.76 Billion | ₩56.23 Billion |
Korean Drug Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Korean Drug Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.44 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 6.1% |
| Total Assets | ₩94.32 Billion |
| Market Capitalization | $24.65 Million USD |
Valuation Analysis
Below Book Valuation: The market values Korean Drug Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Korean Drug Co. Ltd's assets grew by 6.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Korean Drug Co. Ltd (2014–2025)
The table below shows the annual total assets of Korean Drug Co. Ltd from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩94.32 Billion ≈ $63.92 Million |
+6.11% |
| 2024-12-31 | ₩88.89 Billion ≈ $60.24 Million |
-0.92% |
| 2023-12-31 | ₩89.71 Billion ≈ $60.79 Million |
-5.09% |
| 2022-12-31 | ₩94.52 Billion ≈ $64.05 Million |
+6.66% |
| 2021-12-31 | ₩88.61 Billion ≈ $60.05 Million |
+6.32% |
| 2020-12-31 | ₩83.34 Billion ≈ $56.48 Million |
+9.88% |
| 2019-12-31 | ₩75.85 Billion ≈ $51.40 Million |
+3.96% |
| 2018-12-31 | ₩72.96 Billion ≈ $49.45 Million |
+9.23% |
| 2017-12-31 | ₩66.79 Billion ≈ $45.27 Million |
+5.33% |
| 2016-12-31 | ₩63.41 Billion ≈ $42.97 Million |
+7.12% |
| 2015-12-31 | ₩59.20 Billion ≈ $40.12 Million |
-4.79% |
| 2014-12-31 | ₩62.17 Billion ≈ $42.13 Million |
-- |
About Korean Drug Co. Ltd
Korean Drug Co., Ltd. manufactures and sells medicines for treating various diseases in South Korea. The company offers Medicines for urinary tract disease, digestive system, circulatory system, psychonervous system, central nervous system, respiratory system, and skin and subcutaneous system; and antivirals, antibiotics, antifungals, antipyretic, analgesis, anti-inflammatory, and other products.… Read more